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Patients with a pain intensity rating of 40mm on a 100mm Visual
Analog Scale (VAS) were randomized to receive indomethacin submi-
cron particle capsules (40mg TID or BID or 20mg TID), celecoxib (400mg
loading dose; 200mg BID), or placebo. The primary endpoint was the
summed pain intensity difference measured by VAS over 48 hrs (VAS
SPID-48).
Results: Of the 462 patients enrolled, most (83.1%) were women with
a mean age of 41.2 (12.5) years. Indomethacin submicron particle
capsules 40mg TID (509.691.9), 40mg BID (328.092.9), and 20mg TID
(380.592.9) reduced pain (VAS SPID-48; P0.046 for all 3 groups)
compared with placebo (67.891.4; Figure). Although there was some
evidence of analgesia for celecoxib (279.491.9) VAS SPID-48 did not
achieve statistical signiﬁcance compared with placebo. Indomethacin
submicron particle capsules 40mg TID (30.7; P¼0.013) and 40mg BID
(29.8; P¼0.014) achieved better pain control over 4 hrs after study entry
(VAS SPID-4) compared to placebo (8.9). Similarly, indomethacin
submicron particle capsules 40mg TID (2.5; P¼0.003) and 40mg BID
(2.1; P¼0.022) provided greater total pain relief over 4 hrs after study
entry (TOTPAR-4) compared with placebo (1.2). Some evidence of pain
control was observed as early as 30 min (VAS SPID) in the indomethacin
submicron particle capsules 40mg TID (2.9) and 40mg BID (2.6) groups
compared with placebo (0.2). AEs were generally similar across treat-
ment groups and included nausea, localized post-procedural edema,
dizziness, and headache.
ĂConclusions: In this study, investigational lower-dose, indomethacin
submicron particle capsules provided effective pain control compared
with placebo in a post-surgical model of moderate to severe acute pain.
Indomethacin submicron particle capsules are a potentially promising
option for patients with acute pain.
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ACUTE AND SHORT-TERM EFFECTS OF INTRA-ARTICULAR KNEE PAIN
RELIEF ON PAIN SENSITIZATION IN KNEE OA: A COHORT STUDY
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Henriksen y. y The Parker Inst., Dept. of Rheumatology, Copenhagen Univ.Table 1
Test day Day -8 Day 0
Test 1 Test 2
Mean SE Mean
Current knee pain, cm (0-10) 3.0 0.3 2.8
Hand-held algometer, kPa
Corpus Hoffa medial 558.1 23.8 582.1
Corpus Hoffa lateral 611.2 25.3 656.5
Lateral joint line 490.6 17.3 524.6
Quadriceps tendon, lateral 507.6 23.5 527.9
Quadriceps tendon, median 580.2 22.9 597.1
Quadriceps tendon, medial 490.4 21.3 538.3
Medial joint line 506.1 23.3 513.5
Centre of patella 629.0 23.7 669.5
Extensor carpi radialis (control point) 412.0 16.1 430.5Hosp., Frederiksberg, Denmark; zCtr. for Sensory-Motor Interaction,
Dept. of Hlth.Sci. and Technology, Faculty of Med., Aalborg Univ.,
Aalborg, Denmark
Purpose: Pain is the cardinal symptom of knee osteoarthritis (OA).
Recently hyperalgesia and widespread pain was shown in knee OA
patients, as both the knee and surrounding sites were hypersensitive
to pressure pain testing compared with controls. Hyperalgesia and
spontaneous pain in knee OA is most likely related to increased
sensitivity of nociceptors located in deep tissue (peripheral sensitisa-
tion) and/or by increased responses in dorsal horn or supraspinal
neurons (central sensitisation). However, the effects of pain relief on
pain sensitivity in knee OA are unknown. The purpose of this study
was to assess the effects of intra-articular pain relief and anti-
inﬂammation on pain sensitivity in the knee and surrounding tissues
in knee OA patients.
Methods: Twenty-ﬁve consecutive knee OA patients with symptomatic
knee OA according to the ACR criteria were included in this observa-
tional study, with tests of pressure pain thresholds (PPT) before and
after treatment of the knee with intra-articular injection of 40 ml
glucocorticoid (depomedrol 40 mg/ml) and 10 ml lidocaine (10%). The
patients rated their current pain continuously on a visual analogue scale
(VAS), with 0 indicating “no pain” and 10 deﬁned “maximum pain”.
Hand-held, computer-controlled and cuff pressure algometers were
used to assess PPT in the peripatellar region, on vastus lateralis, on
tibialis anterior and the extensor carpi radialis longus muscles (control
site). The PPTs were assessed on day -8 and day 0 before, immediately
after the injection (day 0) and two weeks after the injection (day 14).
Results: The current knee painwas signiﬁcantly lower (see table 1) after
treatment, indicating clinical efﬁcacy of the injection. We found
reduced pain sensitivity (higher PPT levels) following intra-articular
lidocaine (see table 1 and 2 at day 0 - post lidocaine) in both the knee
and in the surrounding muscles, whereas the control assessment site
was not affected by either treatments. There was a trend towards even
greater reduction in pain sensitivity at day 14 after the intra-articular
treatment (see table 1 and 2 at day 14 follow-up) in both the knee and in
the surrounding muscles.
Conclusions: This study shows that intra-articular knee pain relief
leads to reduced pain sensitivity in the knee and surrounding muscles
as well. This effect may be more pronounced after a combination of
anaesthetic action and reduction of inﬂammation. Deeper under-
standing of the underlying mechanisms may inﬂuence the choice of
treatment in the future to avoid or prevent hypersensitivity in knee OA
patients.
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THE REDUCTION OF PAIN BY CHONDROCYTES SECRETING TGF-b1 IN
A RAT MONOSODIUM IODOACETATE (MIA)-INDUCED
OSTEOARTHRITIS MODEL
K.B. Choi, Sr., Hyeon Youl Lee, Dae-Wook Kim, Sujeong Kim. Kolon Life
Sci., Seoul, Republic of KoreaDay 14 P for trend
Post lidocaine Follow-up(post
steroid)
SE Mean SE Mean SE
0.3 1.8 0.3 1.3 0.3 0.0001
23.8 659.6 23.8 689.3 24.2 0.0001
25.3 689.8 25.3 722.9 25.8 0.0057
17.3 601.3 17.3 573.8 17.6 <.0001
23.6 636.8 23.6 560.9 23.9 <.0001
22.9 675.3 22.9 672.8 23.4 0.0011
21.3 625.3 21.3 582.9 21.8 <.0001
23.3 596.5 23.3 568.3 23.6 0.0006
23.7 707.3 23.7 702.3 24.1 0.0341
16.1 452.5 16.1 428.7 16.5 0.3013
